Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypes (Q35827444)

10 August 2017

Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypes (English)

1 reference

10 August 2017

1 reference

0 references

5

Norio Yasui-Furukori

1 reference

10 August 2017

Masatomo Miura

1

1 reference

10 August 2017

Hideaki Kagaya

2

1 reference

10 August 2017

Hitoshi Tada

3

1 reference

10 August 2017

Tsukasa Uno

4

1 reference

10 August 2017

Tomonori Tateishi

6

1 reference

10 August 2017

Toshio Suzuki

7

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 March 2006

1 reference

British Journal of Clinical Pharmacology

10 August 2017

1 reference

10 August 2017

61

1 reference

10 August 2017

3

1 reference

10 August 2017

315-320

1 reference

Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine

10 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885016

Clinical significance of the cytochrome P450 2C19 genetic polymorphism

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885016

Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885016

Pharmacokinetic considerations in the eradication of Helicobacter pylori

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885016

Review article: cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885016

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885016

Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885016

Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885016

Overview of issues related to medical compliance with implications for the outpatient management of infectious diseases

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885016

The potency of substituted benzimidazoles such as E3810, omeprazole, Ro 18-5364 to inhibit gastric H+, K(+)-ATPase is correlatedwith the rate of acid-activation of the inhibitor

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885016

Inhibitions of acid secretion by E3810 and omeprazole, and their reversal by glutathione.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885016

CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects

11 July 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2005.02566.X

Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2005.02566.X

Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2005.02566.X

Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2005.02566.X

Stereospecific analysis of omeprazole in human plasma as a probe for CYP2C19 phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2005.02566.X

Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2005.02566.X

Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2005.02566.X

Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4'-hydroxylation status

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/16487225

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/16487225

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/16487225

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1111/J.1365-2125.2005.02566.X

1 reference

10 August 2017

1 reference

10 August 2017

1 reference